Investor Presentaiton

Broad and innovative pipeline to address significant unmet medical needs. Phase 2 Oncology Phase 3 KEYTRUDA (MK-3475) CSCC (EU) LENVIMA (MK-7902) Esophageal Gastric LYNPARZA (MK-7339) NSCLC SCLC MK-1026 (nemtabrutinib) WELIREG (MK-6482) Hematological Malignancies RCC (EU) MK-1308A (quavonlimab MK-7684A (vibostolimab Melanoma +pembrolizumab) NSCLC +pembrolizumab) TUKYSA (MK-7119) Breast CRC MK-3475A (pembrolizumab +hyaluronidase) NSCLC V940 Melanoma Under regulatory review Oncology KEYTRUDA (MK-3475) 2L HCC (US) LA Cervical (US) Resectable NSCLC (EU, JPN) 1L HER2- Gastric (US, EU, JPN) 1L Biliary (US, EU, JPN) WELIREG (MK-6482) Advanced RCC (US) General medicine Gefapixant (MK-7264) Cough (US) PREVYMIS (MK-8228) Prophylaxis of CMV in kidney transplant patients (EU) Cardiovascular MK-7962 (sotatercept) Pulmonary Arterial Hypertension (US) Oncology MK-0482 NSCLC MK-1308 (quavonlimab) NSCLC MK-1308A KEYTRUDA (MK-3475) MK-4830 Advanced Solid Tumors CRC WELIREG (MK-6482) Biliary MK-7684A (vibostolimab Prostate Esophageal Melanoma Certain VHL tumors (EU) +pembrolizumab) CRC Hepatocellular (EU) Biliary Mesothelioma MK-3543 NSCLC Endometrial Bladder Ovarian (bomedemstat) Ovarian Esophageal SCLC Breast Myeloproliferative RCC HCC Cervical (quavonlimab Disorders SCLC Pancreatic CRC +pembrolizumab) Rare Cancers Endometrial CRC MK-4280 MK-5684 SCLC (favezelimab) Esophageal Prostate TUKYSA (MK-7119) Gastric NSCLC Advanced Solid Tumors MK-2140 (zilovertamab HCC +pembrolizumab) MK-5890 (boserolimab) Bladder RCC vedotin) MK-4280A HNSCC NSCLC Bladder (favezelimab+pembroli Biliary SCLC Cervical Breast zumab) Ovarian Prostate Endometrial Gastric Bladder LYNPARZA (MK-7339) Gastric Hematological Malignancies cSCC Advanced Solid Tumors NSCLC NSCLC Esophageal Ovarian Melanoma LENVIMA (MK-7902) Pancreas RCC Biliary SCLC HNSCC MK-2870 Pancreas Neoplasm Malignant Vaccines V181 Dengue Virus Infectious diseases MK-8591B (islatravir+MK-8507)¹ HIV-1 Infection MK-8591D (islatravir+lenacapavir)² HIV-1 Infection Prostate SCLC Cardiovascular MK-2060 Thrombosis MK-5475 Pulmonary Arterial Hypertension MK-7962 (sotatercept) Pulmonary Hypertension due to Left Heart Disease 1On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials 3 Available in the US under EUA 4Development is co-funded by Royalty Pharma Note: Pipeline does not include the three DXd ADCs from the collaboration with Daiichi Sankyo General medicine MK-6024 (efinopegdutide) NASH Neuroscience MK-81894 Schizophrenia SCLC MK-4280A (favezelimab CRC Hematological Malignancies Infectious diseases MK-8591A (doravirine+islatravir)² HIV-1 Infection Vaccines MK-1654 (clesrovimab) Respiratory Syncytial Virus (RSV) Cardiovascular MK-7962 (sotatercept) Pulmonary Arterial Hypertension (EU) Immunology MK-7240 Ulcerative Colitis LAGEVRIO (MK-4482)³ COVID-19 antiviral V116 Pneumococcal vaccine, adult MK-0616 Hypercholesterolemia 31 As of October 26, 2023

View entire presentation